Results 171 to 180 of about 33,513 (195)

Topical Losartan in Ophthalmology: Rationale, Experimental and Clinical Evidence, and Emerging Clinical Applications. [PDF]

J Clin Med
Burgos-Blasco B, Molero-Senosiain M, Perez-Garcia P, Ariño-Gutierrez M, Arriola-Villalobos P, Diaz-Valle D.   +5 more
europepmc   +1 more source

Inactivation of SERCA2 at Cys674 induces skeletal muscle atrophy by activating the TGFβ/Smad-S100a4 axis to promote inflammation. [PDF]

Redox Biol
Nan F, Liu S, Lei S, Peng Y, Zhang H, Chen X, Jin S, Mao Y, Lin D, Tong X, Qu Y.   +10 more
europepmc   +1 more source

Topical losartan to prevent stromal scarring during post-cross-linking infection in pediatric keratoconus: A case report. [PDF]

Am J Ophthalmol Case Rep
Barzaghi F, Kronschläger M, Amir-Asgari S, Findl O.   +3 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Long-term clinical outcomes of losartan in patients with Marfan syndrome: follow-up of the multicentre randomized controlled COMPARE trial

European Heart Journal, 2020
Ron Balm, Reza Indrakusuma, Hamid Jalalzadeh   +2 more
exaly  

Losartan in Heart Failure

Circulation, 1995
K Dickstein
exaly  

Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE)

Lancet, The, 1997
Bertram Pitt, Prakash C Deedwania, P C Deedwania   +2 more
exaly  

Effects of losartan and candesartan monotherapy and losartan/hydrochlorothiazide combination therapy in patients with mild to moderate hypertension

Clinical Therapeutics, 2000
Ehud Grossman, Bojan Jelaković, Thomas Dumortier   +2 more
exaly